Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma bio...
Gespeichert in:
| Veröffentlicht in: | Annals of neurology 2024-09, Vol.96 (3), p.453-459 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 3 |
| container_start_page | 453 |
| container_title | Annals of neurology |
| container_volume | 96 |
| creator | Brier, Matthew R Schindler, Suzanne E Salter, Amber Perantie, Dana Shelley, Nicole Judge, Bradley Keefe, Sarah Kirmess, Kristopher M Verghese, Philip B Yarasheski, Kevin E Venkatesh, Venky Raji, Cyrus A Gordon, Brian A Bateman, Randall J Morris, John C Naismith, Robert T Holtzman, David M Benzinger, Tammie L S Cross, Anne H |
| description | The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459. |
| doi_str_mv | 10.1002/ana.27027 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3075703656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3075703656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c203t-2e8157e8250cc69ed21374a38eb3abac50cdf4f8d180c86ef8ee607626acdab83</originalsourceid><addsrcrecordid>eNpdkMtOwzAQRS0EoqWw4AeQJTawSPEjsZ0lqniqCAR0HTnOBFI5cYkTQX-LD-GbcGlhwWqkmaOruQehQ0rGlBB2phs9ZpIwuYWGNOE0UixOt9GQcBFHCeXxAO15PyeEpIKSXTTgKhWcJWKIbmcNfCzAdFDgqXvHj7oD7Ep8Xi-tq4ro6xM_6O7VWfeyxFWD73rbVQsL-MlYaJ2v_OpeQdP5fbRTauvhYDNHaHZ58Ty5jqb3VzeT82lkGOFdxEDRRIJiCTFGpFAwymWsuYKc61ybsC7KuFQFVcQoAaUCEEQKJrQpdK74CJ2scxete-vBd1ldeQPW6gZc7zNOZCJD9UQE9PgfOnd924TvApUyIYUMekbodE2ZUMi3UGaLtqp1u8woyVaCsyA4-xEc2KNNYp_XUPyRv0b5N3Qtdd8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3092676751</pqid></control><display><type>article</type><title>Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Brier, Matthew R ; Schindler, Suzanne E ; Salter, Amber ; Perantie, Dana ; Shelley, Nicole ; Judge, Bradley ; Keefe, Sarah ; Kirmess, Kristopher M ; Verghese, Philip B ; Yarasheski, Kevin E ; Venkatesh, Venky ; Raji, Cyrus A ; Gordon, Brian A ; Bateman, Randall J ; Morris, John C ; Naismith, Robert T ; Holtzman, David M ; Benzinger, Tammie L S ; Cross, Anne H</creator><creatorcontrib>Brier, Matthew R ; Schindler, Suzanne E ; Salter, Amber ; Perantie, Dana ; Shelley, Nicole ; Judge, Bradley ; Keefe, Sarah ; Kirmess, Kristopher M ; Verghese, Philip B ; Yarasheski, Kevin E ; Venkatesh, Venky ; Raji, Cyrus A ; Gordon, Brian A ; Bateman, Randall J ; Morris, John C ; Naismith, Robert T ; Holtzman, David M ; Benzinger, Tammie L S ; Cross, Anne H</creatorcontrib><description>The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.</description><identifier>ISSN: 0364-5134</identifier><identifier>ISSN: 1531-8249</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.27027</identifier><identifier>PMID: 38963256</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Alzheimer Disease - blood ; Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimer's disease ; Amyloid beta-Peptides - blood ; Amyloid beta-Peptides - metabolism ; Apolipoprotein E ; Autoimmune diseases ; Biomarkers ; Biomarkers - blood ; Dementia disorders ; Female ; Health risks ; Humans ; Life expectancy ; Life span ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - blood ; Multiple Sclerosis - pathology ; Neurodegenerative diseases ; Pathology ; β-Amyloid</subject><ispartof>Annals of neurology, 2024-09, Vol.96 (3), p.453-459</ispartof><rights>2024 American Neurological Association.</rights><rights>2024 American Neurological Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c203t-2e8157e8250cc69ed21374a38eb3abac50cdf4f8d180c86ef8ee607626acdab83</cites><orcidid>0000-0002-5943-0940 ; 0000-0001-5987-8705 ; 0000-0003-2109-2955 ; 0000-0002-1088-110X ; 0000-0003-0829-7569 ; 0000-0002-8114-0552</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38963256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brier, Matthew R</creatorcontrib><creatorcontrib>Schindler, Suzanne E</creatorcontrib><creatorcontrib>Salter, Amber</creatorcontrib><creatorcontrib>Perantie, Dana</creatorcontrib><creatorcontrib>Shelley, Nicole</creatorcontrib><creatorcontrib>Judge, Bradley</creatorcontrib><creatorcontrib>Keefe, Sarah</creatorcontrib><creatorcontrib>Kirmess, Kristopher M</creatorcontrib><creatorcontrib>Verghese, Philip B</creatorcontrib><creatorcontrib>Yarasheski, Kevin E</creatorcontrib><creatorcontrib>Venkatesh, Venky</creatorcontrib><creatorcontrib>Raji, Cyrus A</creatorcontrib><creatorcontrib>Gordon, Brian A</creatorcontrib><creatorcontrib>Bateman, Randall J</creatorcontrib><creatorcontrib>Morris, John C</creatorcontrib><creatorcontrib>Naismith, Robert T</creatorcontrib><creatorcontrib>Holtzman, David M</creatorcontrib><creatorcontrib>Benzinger, Tammie L S</creatorcontrib><creatorcontrib>Cross, Anne H</creatorcontrib><title>Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.</description><subject>Adult</subject><subject>Aged</subject><subject>Alzheimer Disease - blood</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Peptides - blood</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Apolipoprotein E</subject><subject>Autoimmune diseases</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Dementia disorders</subject><subject>Female</subject><subject>Health risks</subject><subject>Humans</subject><subject>Life expectancy</subject><subject>Life span</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - blood</subject><subject>Multiple Sclerosis - pathology</subject><subject>Neurodegenerative diseases</subject><subject>Pathology</subject><subject>β-Amyloid</subject><issn>0364-5134</issn><issn>1531-8249</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkMtOwzAQRS0EoqWw4AeQJTawSPEjsZ0lqniqCAR0HTnOBFI5cYkTQX-LD-GbcGlhwWqkmaOruQehQ0rGlBB2phs9ZpIwuYWGNOE0UixOt9GQcBFHCeXxAO15PyeEpIKSXTTgKhWcJWKIbmcNfCzAdFDgqXvHj7oD7Ep8Xi-tq4ro6xM_6O7VWfeyxFWD73rbVQsL-MlYaJ2v_OpeQdP5fbRTauvhYDNHaHZ58Ty5jqb3VzeT82lkGOFdxEDRRIJiCTFGpFAwymWsuYKc61ybsC7KuFQFVcQoAaUCEEQKJrQpdK74CJ2scxete-vBd1ldeQPW6gZc7zNOZCJD9UQE9PgfOnd924TvApUyIYUMekbodE2ZUMi3UGaLtqp1u8woyVaCsyA4-xEc2KNNYp_XUPyRv0b5N3Qtdd8</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Brier, Matthew R</creator><creator>Schindler, Suzanne E</creator><creator>Salter, Amber</creator><creator>Perantie, Dana</creator><creator>Shelley, Nicole</creator><creator>Judge, Bradley</creator><creator>Keefe, Sarah</creator><creator>Kirmess, Kristopher M</creator><creator>Verghese, Philip B</creator><creator>Yarasheski, Kevin E</creator><creator>Venkatesh, Venky</creator><creator>Raji, Cyrus A</creator><creator>Gordon, Brian A</creator><creator>Bateman, Randall J</creator><creator>Morris, John C</creator><creator>Naismith, Robert T</creator><creator>Holtzman, David M</creator><creator>Benzinger, Tammie L S</creator><creator>Cross, Anne H</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5943-0940</orcidid><orcidid>https://orcid.org/0000-0001-5987-8705</orcidid><orcidid>https://orcid.org/0000-0003-2109-2955</orcidid><orcidid>https://orcid.org/0000-0002-1088-110X</orcidid><orcidid>https://orcid.org/0000-0003-0829-7569</orcidid><orcidid>https://orcid.org/0000-0002-8114-0552</orcidid></search><sort><creationdate>202409</creationdate><title>Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients</title><author>Brier, Matthew R ; Schindler, Suzanne E ; Salter, Amber ; Perantie, Dana ; Shelley, Nicole ; Judge, Bradley ; Keefe, Sarah ; Kirmess, Kristopher M ; Verghese, Philip B ; Yarasheski, Kevin E ; Venkatesh, Venky ; Raji, Cyrus A ; Gordon, Brian A ; Bateman, Randall J ; Morris, John C ; Naismith, Robert T ; Holtzman, David M ; Benzinger, Tammie L S ; Cross, Anne H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c203t-2e8157e8250cc69ed21374a38eb3abac50cdf4f8d180c86ef8ee607626acdab83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alzheimer Disease - blood</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Peptides - blood</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Apolipoprotein E</topic><topic>Autoimmune diseases</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Dementia disorders</topic><topic>Female</topic><topic>Health risks</topic><topic>Humans</topic><topic>Life expectancy</topic><topic>Life span</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - blood</topic><topic>Multiple Sclerosis - pathology</topic><topic>Neurodegenerative diseases</topic><topic>Pathology</topic><topic>β-Amyloid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brier, Matthew R</creatorcontrib><creatorcontrib>Schindler, Suzanne E</creatorcontrib><creatorcontrib>Salter, Amber</creatorcontrib><creatorcontrib>Perantie, Dana</creatorcontrib><creatorcontrib>Shelley, Nicole</creatorcontrib><creatorcontrib>Judge, Bradley</creatorcontrib><creatorcontrib>Keefe, Sarah</creatorcontrib><creatorcontrib>Kirmess, Kristopher M</creatorcontrib><creatorcontrib>Verghese, Philip B</creatorcontrib><creatorcontrib>Yarasheski, Kevin E</creatorcontrib><creatorcontrib>Venkatesh, Venky</creatorcontrib><creatorcontrib>Raji, Cyrus A</creatorcontrib><creatorcontrib>Gordon, Brian A</creatorcontrib><creatorcontrib>Bateman, Randall J</creatorcontrib><creatorcontrib>Morris, John C</creatorcontrib><creatorcontrib>Naismith, Robert T</creatorcontrib><creatorcontrib>Holtzman, David M</creatorcontrib><creatorcontrib>Benzinger, Tammie L S</creatorcontrib><creatorcontrib>Cross, Anne H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brier, Matthew R</au><au>Schindler, Suzanne E</au><au>Salter, Amber</au><au>Perantie, Dana</au><au>Shelley, Nicole</au><au>Judge, Bradley</au><au>Keefe, Sarah</au><au>Kirmess, Kristopher M</au><au>Verghese, Philip B</au><au>Yarasheski, Kevin E</au><au>Venkatesh, Venky</au><au>Raji, Cyrus A</au><au>Gordon, Brian A</au><au>Bateman, Randall J</au><au>Morris, John C</au><au>Naismith, Robert T</au><au>Holtzman, David M</au><au>Benzinger, Tammie L S</au><au>Cross, Anne H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>96</volume><issue>3</issue><spage>453</spage><epage>459</epage><pages>453-459</pages><issn>0364-5134</issn><issn>1531-8249</issn><eissn>1531-8249</eissn><abstract>The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38963256</pmid><doi>10.1002/ana.27027</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-5943-0940</orcidid><orcidid>https://orcid.org/0000-0001-5987-8705</orcidid><orcidid>https://orcid.org/0000-0003-2109-2955</orcidid><orcidid>https://orcid.org/0000-0002-1088-110X</orcidid><orcidid>https://orcid.org/0000-0003-0829-7569</orcidid><orcidid>https://orcid.org/0000-0002-8114-0552</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-5134 |
| ispartof | Annals of neurology, 2024-09, Vol.96 (3), p.453-459 |
| issn | 0364-5134 1531-8249 1531-8249 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3075703656 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Alzheimer Disease - blood Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer's disease Amyloid beta-Peptides - blood Amyloid beta-Peptides - metabolism Apolipoprotein E Autoimmune diseases Biomarkers Biomarkers - blood Dementia disorders Female Health risks Humans Life expectancy Life span Male Middle Aged Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - pathology Neurodegenerative diseases Pathology β-Amyloid |
| title | Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A51%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unexpected%20Low%20Rate%20of%20Amyloid-%CE%B2%20Pathology%20in%20Multiple%20Sclerosis%20Patients&rft.jtitle=Annals%20of%20neurology&rft.au=Brier,%20Matthew%20R&rft.date=2024-09&rft.volume=96&rft.issue=3&rft.spage=453&rft.epage=459&rft.pages=453-459&rft.issn=0364-5134&rft.eissn=1531-8249&rft_id=info:doi/10.1002/ana.27027&rft_dat=%3Cproquest_cross%3E3075703656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3092676751&rft_id=info:pmid/38963256&rfr_iscdi=true |